Progen Co., Ltd. (XKON:296160)
South Korea · Delayed Price · Currency is KRW 2,670.00
+105.00 (4.09%)
At close: Sep 3, 2026
Progen Revenue
In the year 2022, Progen had annual revenue of 450.00M KRW, down -67.36%.
Revenue
450.00M
Revenue Growth
-67.36%
P/S Ratio
92.08
Revenue / Employee
n/a
Employees
n/a
Market Cap
41.44B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 450.00M | -928.70M | -67.36% |
| Dec 31, 2021 | 1.38B | -179.40M | -11.51% |
| Dec 31, 2020 | 1.56B | 1.21B | 345.17% |
| Dec 31, 2019 | 350.00M | 325.00M | 1,300.00% |
| Dec 31, 2018 | 25.00M | -482.76M | -95.08% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| KoBioLabs | 75.41B |
| Eutilex.Co.,Ltd | 7.71B |
| QuadMedicine | 7.14B |
| TegoScience | 6.18B |
| HLB Pep | 5.54B |
| Parataxis Korea | 1.59B |
| Kainos Medicine | 1.40B |
| NovMetaPharma | 1.30B |